Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Top Pharma List methodology page

  • The Top Pharma List is based on data provided by research and consulting firm GlobalData.
  • The current version of the data ranks companies based on information from GlobalData Pharma Intelligence Center’s Sales Analytics Database, as shown on July 7, 2017.
  • Figures for the period 2018-23 are a forecast, but only show the performance of those companies featured in the 2017 ranking.

US/Japan/Europe Rx

  • These lists rank the top companies based on geographic-specific sales.

Products

  • Product sales are mapped to the parent company, rather than subsidiary companies, as they are reported in the annual reports of the parent company itself.
  • For example, ViiV Healthcare (whose partners include Pfizer and Shionogi) operates as a subsidiary of GSK, so sales for ViiV’s Triumeq have been attributed to GSK.
  • Similarly, Xtandi is attributed to Astellas not Pfizer and Imbruvica is attributed to AbbVie rather than Johnson & Johnson.
  • Finally, sales of Eliquis are reported separately by both Bristol-Myers Squibb and Pfizer and so appears twice in the top product ranking, as does Enbrel with sales as reported by Amgen and Pfizer.

Therapy area sales

  • The sales data provided are not indication-specific where drugs are approved, or in development, for multiple indications. Instead they’re based on GlobalData’s Key Therapy Area classification, which places products into a single therapeutic area based on its corporate positioning and/or mechanism of action.
  • However, product sales may contribute to more than one sales segment, eg biologics and oncology, in which can sales segments for a company may add up to more than its total sales.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...